A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Chroma Dex Corp. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,900 shares of CDXC stock, worth $58,353. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,900
Previous 25,800 30.62%
Holding current value
$58,353
Previous $89,000 46.07%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.44 - $4.32 $75,837 - $134,269
-31,081 Reduced 75.75%
9,952 $27,000
Q1 2024

May 15, 2024

SELL
$1.36 - $3.84 $188,580 - $532,462
-138,662 Reduced 77.17%
41,033 $142,000
Q4 2023

Feb 14, 2024

BUY
$1.28 - $1.6 $8,864 - $11,080
6,925 Added 4.01%
179,695 $256,000
Q3 2023

Nov 14, 2023

SELL
$1.36 - $1.77 $19,642 - $25,564
-14,443 Reduced 7.71%
172,770 $252,000
Q2 2023

Aug 14, 2023

SELL
$1.31 - $1.79 $29,840 - $40,774
-22,779 Reduced 10.85%
187,213 $293,000
Q1 2023

May 15, 2023

BUY
$1.48 - $2.19 $88,357 - $130,745
59,701 Added 39.72%
209,992 $321,000
Q4 2022

Feb 14, 2023

BUY
$1.46 - $1.94 $136,839 - $181,828
93,726 Added 165.7%
150,291 $252,000
Q3 2022

Nov 14, 2022

SELL
$1.21 - $2.06 $383,560 - $653,003
-316,992 Reduced 84.86%
56,565 $70,000
Q2 2022

Aug 15, 2022

BUY
$1.59 - $2.7 $420,520 - $714,090
264,478 Added 242.46%
373,557 $623,000
Q1 2022

May 16, 2022

SELL
$2.02 - $3.92 $77,050 - $149,524
-38,144 Reduced 25.91%
109,079 $268,000
Q4 2021

Feb 14, 2022

BUY
$3.74 - $6.7 $419,841 - $752,121
112,257 Added 321.05%
147,223 $550,000
Q3 2021

Nov 15, 2021

BUY
$6.05 - $10.41 $34,727 - $59,753
5,740 Added 19.64%
34,966 $219,000
Q2 2021

Aug 16, 2021

SELL
$6.66 - $10.92 $293,579 - $481,364
-44,081 Reduced 60.13%
29,226 $288,000
Q1 2021

May 17, 2021

BUY
$4.59 - $18.74 $336,479 - $1.37 Million
73,307 New
73,307 $685,000
Q3 2020

Nov 16, 2020

SELL
$4.01 - $5.56 $119,113 - $165,154
-29,704 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$3.0 - $5.52 $131,253 - $241,505
-43,751 Reduced 59.56%
29,704 $137,000
Q1 2020

May 15, 2020

BUY
$2.54 - $4.75 $133,108 - $248,923
52,405 Added 248.95%
73,455 $239,000
Q4 2018

Feb 14, 2019

SELL
$2.8 - $4.22 $65,200 - $98,266
-23,286 Reduced 52.52%
21,050 $72,000
Q3 2018

Nov 13, 2018

BUY
$3.5 - $4.91 $95,602 - $134,116
27,315 Added 160.48%
44,336 $0
Q2 2018

Aug 10, 2018

SELL
$3.22 - $4.43 $136,267 - $187,473
-42,319 Reduced 71.32%
17,021 $0
Q1 2018

May 11, 2018

BUY
$4.05 - $6.46 $240,327 - $383,336
59,340 New
59,340 $249,000

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $223M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.